Apple Turns 50: From Garage Startup to AI Crossroads 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
BURLINGAME, Calif., Jan. 04, 2017 -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the 35th Annual J.P. Morgan Healthcare Conference 2017 in San Francisco. The presentation is scheduled for Thursday, January 12, at 8:00 a.m. Pacific Time.
A webcast of the presentation will be available live and for 7 days following the event. The webcast may be accessed via the conference direct link and from the investor relations section of Corvus’ website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.
Corvus Contact: Jason Coloma SVP, Chief Business Officer Corvus Pharmaceuticals, Inc. 650-900-4511 [email protected] Media Contact: Julie Normart BrewLife +1-415-946-1087 [email protected]
